Alan P. Venook

42.4k total citations · 7 hit papers
365 papers, 17.5k citations indexed

About

Alan P. Venook is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alan P. Venook has authored 365 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 255 papers in Oncology, 98 papers in Hepatology and 97 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alan P. Venook's work include Colorectal Cancer Treatments and Studies (139 papers), Hepatocellular Carcinoma Treatment and Prognosis (96 papers) and Pancreatic and Hepatic Oncology Research (52 papers). Alan P. Venook is often cited by papers focused on Colorectal Cancer Treatments and Studies (139 papers), Hepatocellular Carcinoma Treatment and Prognosis (96 papers) and Pancreatic and Hepatic Oncology Research (52 papers). Alan P. Venook collaborates with scholars based in United States, Canada and Japan. Alan P. Venook's co-authors include Richard M. Goldberg, Richard L. Schilsky, Francis Y. Yao, John P. Roberts, Nancy L. Ascher, Junji Furuse, Christos N. Papandreou, Laura Ladrón de Guevara, Nathan M. Bass and Linda D. Ferrell and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Alan P. Venook

352 papers receiving 17.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival

2001 1.6k citations Francis Y. Yao, Alan P. Venook et al. profile →
Cetuximab in the treatment of colorectal cancer.

2004 1.3k citations Richard M. Goldberg, Alan P. Venook et al. profile →
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

2010 790 citations Alan P. Venook, Christos N. Papandreou et al. profile →
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

2017 554 citations Heinz‐Josef Lenz, Alan P. Venook et al. profile →
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

2015 382 citations Chloé E. Atreya, Alan P. Venook et al. Journal of Clinical Oncology profile →
Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer

2019 347 citations Sorbarikor Piawah, Alan P. Venook profile →
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

2022 144 citations Qian Shi, Spencer C. Behr et al. profile →

Peers

Countries citing papers authored by Alan P. Venook

Since Specialization

Citations

This map shows the geographic impact of Alan P. Venook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan P. Venook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan P. Venook more than expected).

Fields of papers citing papers by Alan P. Venook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan P. Venook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan P. Venook. The network helps show where Alan P. Venook may publish in the future.

Co-authorship network of co-authors of Alan P. Venook

This figure shows the co-authorship network connecting the top 25 collaborators of Alan P. Venook. A scholar is included among the top collaborators of Alan P. Venook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan P. Venook. Alan P. Venook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202) 2025 ·Journal of Clinical Oncology ·Emily K. Bergsland, Susan Geyer, Timothy R. Asmis, Spencer C. Behr, J. Philip Kuebler, Priya Kumthekar, Gina L. Mazza, Michael L. Maitland, Donna Niedzwiecki, Andrew B. Nixon, Lawrence H. Schwartz, Jonathan Strosberg, Alan P. Venook, Eileen M. O’Reilly, Jeffrey A. Meyerhardt	0
2	Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity 2025 ·Science Translational Medicine ·(unknown), (unknown), Than S. Kyaw, (unknown), C. Anders Olson, (unknown), Cecilia Noecker, Vaibhav Upadhyay, (unknown), (unknown), (unknown), Peter Spanogiannopoulos, Darren S. Dumlao, (unknown), Matthew D. Stachler, Erin L. Van Blarigan, Alan P. Venook, Chloé E. Atreya, Peter J. Turnbaugh	2
3	q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics 2024 ·Communications Biology ·(unknown), Russell Littman, Francesca Battaglin, Donna Niedzwiecki, Alan P. Venook, José Luis Ambite, Aram Galstyan, Heinz‐Josef Lenz, Greg Ver Steeg	0
4	Plant-based diet and survival among patients with metastatic colorectal cancer 2024 ·JNCI Journal of the National Cancer Institute ·En Cheng, Fang‐Shu Ou, (unknown), (unknown), Alan P. Venook, Heinz‐Josef Lenz, Eileen M. O’Reilly, Peter T. Campbell, Chaoyuan Kuang, Bette J. Caan, Charles D. Blanke, Kimmie Ng, Jeffrey A. Meyerhardt	7
5	Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma—a real-world, multicenter study 2024 ·Therapeutic Advances in Medical Oncology ·Michael Li, Lindsay M. Hannan, Lipika Goyal, Andrea Grace Bocobo, Anna L. Parks, (unknown), Islam Baiev, (unknown), John D. Gordan, Alan P. Venook, (unknown), Paige M. Bracci, Robin Kate Kelley	1
6	DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations 2023 ·Journal of Clinical Oncology ·Federico Innocenti, (unknown), Xueping Qu, Fang‐Shu Ou, Omar Kabbarah, Charles D. Blanke, Alan P. Venook, Heinz‐Josef Lenz, Naim U. Rashid	5
7	Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702 2022 ·Journal of Clinical Oncology ·Seohyuk Lee, (unknown), Qian Shi, Pankaj Kumar, Félix Couture, Philip Kuebler, Smitha Krishnamurthi, DeQuincy Andrew Lewis, Benjamin Kye Jyn Tan, Richard M. Goldberg, Alan P. Venook, Charles D. Blanke, Eileen M. O’Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt	10
8	ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer 2022 ·Nature Communications ·Radia Marie Johnson, Xueping Qu, (unknown), Ling‐Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang‐Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, (unknown), Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz‐Josef Lenz, Carlos Bais	24
9	Association between adherence to the American Cancer Society Nutrition and Physical Activity Guidelines and stool frequency among colon cancer survivors: a cohort study 2022 ·Journal of Cancer Survivorship ·(unknown), Irina Tolstykh, Katherine Van Loon, Angela Laffan, (unknown), (unknown), Stacey A. Kenfield, June M. Chan, Chloé E. Atreya, Sorbarikor Piawah, (unknown), Alan P. Venook, Erin L. Van Blarigan, Madhulika G. Varma	8
10	Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance) 2022 ·Journal of Clinical Oncology ·Kanwal Raghav, Fang‐Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz‐Josef Lenz, Scott Kopetz	25
11	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance) 2020 ·Clinical Cancer Research ·Federico Innocenti, Alexander B. Sibley, (unknown), Amy S. Etheridge, Chen Jiang, Fang‐Shu Ou, (unknown), Sarah J. Plummer, Graham Casey, Monica M. Bertagnolli, Howard L. McLeod, J. Todd Auman, Charles D. Blanke, Yoichi Furukawa, Alan P. Venook, Michiaki Kubo, Heinz‐Josef Lenz, Joel S. Parker, Mark J. Ratain, Kouros Owzar	13
12	Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer 2020 ·Clinical Cancer Research ·Jim Abraham, Daniel Magee, Chiara Cremolini, Carlotta Antoniotti, (unknown), Joanne Xiu, Phillip Stafford, Donald A. Berry, Matthew J. Oberley, Anthony F. Shields, John L. Marshall, Mohamed E. Salem, Alfredo Falcone, Axel Grothey, Michael J. Hall, Alan P. Venook, Heinz‐Josef Lenz, (unknown), W. Michael Korn, David Spetzler	35
13	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405 2020 ·JNCI Cancer Spectrum ·Brendan J. Guercio, Sui Zhang, Alan P. Venook, Fang‐Shu Ou, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, (unknown), Bert H. O’Neil, James E. Shaw, Blasé N. Polite, Howard S. Höchster, James N. Atkins, Richard M. Goldberg, Justin C. Brown, Eileen M. O’Reilly, Robert J. Mayer, Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt	8
14	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance) 2019 ·Clinical Cancer Research ·Chen Yuan, Kaori Sato, Bruce W. Hollis, Sui Zhang, Donna Niedzwiecki, Fang‐Shu Ou, (unknown), Bert H. O’Neil, Federico Innocenti, Heinz‐Josef Lenz, Charles D. Blanke, Richard M. Goldberg, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kimmie Ng	44
15	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors 2018 ·Molecular Cancer Therapeutics ·Chester E. Chamberlain, Michael S. German, Katherine Yang, Jason Wang, Henry F. VanBrocklin, (unknown), Kevan M. Shokat, Gregory S. Ducker, Grace Kim, Byron Hann, David B. Donner, Robert S. Warren, Alan P. Venook, Emily K. Bergsland, Danny Lee, Yucheng Wang, Eric K. Nakakura	34
16	Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study 2016 ·Journal of Hepatology ·Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao‐Ping Chen, Lucy Dagher, Junji Furuse, Jean-François H. Geschwind, Laura Ladrón de Guevara, Christos N. Papandreou, Tadatoshi Takayama, Arun J. Sanyal, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni	264
17	A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma 2015 ·Clinical Cancer Research ·Andrew H. Ko, Tanios Bekaii‐Saab, Jessica Van Ziffle, Olga K. Mirzoeva, Nancy M. Joseph, AmirAli Talasaz, Peter Kühn, Margaret A. Tempero, Eric A. Collisson, Robin Kate Kelley, Alan P. Venook, Elizabeth Dito, (unknown), (unknown), (unknown), (unknown), Sanaa Tahiri, W. Michael Korn	100
18	Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) 2014 ·Clinical Cancer Research ·(unknown), Chen Jiang, Ace J. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, Andrew B. Nixon	66
19	Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581 2013 ·Journal of Clinical Oncology ·Alan P. Venook, Donna Niedzwiecki, Margarita Lopatin, Xing Ye, Mark Lee, Paula N. Friedman, Wendy L. Frankel, Kim M. Clark-Langone, Carl Millward, Steven Shak, Richard M. Goldberg, Najjia N. Mahmoud, Robert S. Warren, Richard L. Schilsky, Monica M. Bertagnolli	117
20	Hepatocellular carcinoma: Ablate and wait versus rapid transplantation 2010 ·Liver Transplantation ·John P. Roberts, Alan P. Venook, Robert K. Kerlan, Francis Y. Yao	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact